Perspective Net Interest Income from 2010 to 2026
| CATX Stock | 5.10 0.10 1.92% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 12 M | Current Value 12.6 M | Quarterly Volatility 4.5 M |
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Total Revenue of 0.0 or Gross Profit of 1.2 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 0.6. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
Perspective | Net Interest Income | Build AI portfolio with Perspective Stock |
The evolution of Net Interest Income for Perspective Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Perspective Therapeutics compares to historical norms and industry peers.
Latest Perspective Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Perspective Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Perspective Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Perspective Net Interest Income Regression Statistics
| Arithmetic Mean | 2,236,644 | |
| Geometric Mean | 283,186 | |
| Coefficient Of Variation | 203.27 | |
| Mean Deviation | 3,345,061 | |
| Median | 108,000 | |
| Standard Deviation | 4,546,394 | |
| Sample Variance | 20.7T | |
| Range | 12.6M | |
| R-Value | 0.69 | |
| Mean Square Error | 11.6T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 618,724 | |
| Total Sum of Squares | 330.7T |
Perspective Net Interest Income History
About Perspective Therapeutics Financial Statements
Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 12 M | 12.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.